

Andrea De Luca

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6970593/andrea-de-luca-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341
papers

12,107
citations

53
h-index

97
g-index

351
ext. papers

13,430
ext. citations

5.9
avg, IF

5.35
L-index

#	Paper	IF	Citations
341	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106406	14.3	1
340	Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 194-199	5.1	0
339	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. <i>Infezioni in Medicina</i> , 2020 , 28, 576-586	3.6	
338	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019 , 19, 1291	4.1	3
337	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227	5.4	24
336	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019 , 19, 59	4	13
335	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts $\geq 5 \log_{10}$ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2732-2741	5.1	5
334	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019 , 35, 661-666	2.5	1
333	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , 2019 , 169, 104552	10.8	13
332	Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. <i>Journal of NeuroVirology</i> , 2019 , 25, 866-873	3.9	2
331	Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 453-462	6.2	2
330	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. <i>Aids</i> , 2019 , 33, 315-326	3.5	2
329	Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. <i>PLoS ONE</i> , 2019 , 14, e0225381	3.7	2
328	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, e17-e21	3.1	2
327	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2019 , 6, e116-e127	7.8	53
326	A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. <i>Antiviral Therapy</i> , 2019 , 24, 63-67	1.6	23
325	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , 2018 , 20, 75-82	1.5	2

324	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25083	5.4	7
323	Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 713-738	4	28
322	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. <i>Lancet HIV, the</i> , 2018 , 5, e146-e154	7.8	45
321	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 871-881	5.3	2
320	HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. <i>Journal of Clinical Virology</i> , 2018 , 103, 57-62	14.5	2
319	Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 308.e5-308.e8	9.5	7
318	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
317	Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. <i>HIV Medicine</i> , 2018 , 19, 619-628	2.7	21
316	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018 , 16, 79	11.4	16
315	A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach. <i>PLoS ONE</i> , 2018 , 13, e0200892	3.7	5
314	Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis. <i>Journal of Clinical Virology</i> , 2018 , 106, 49-52	14.5	6
313	Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2927-2935	5.1	13
312	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018 , 18, 870	4.1	13
311	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30
310	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113	1	34
309	3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. <i>Antiviral Therapy</i> , 2018 , 23, 139-148	1.6	6
308	Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-world large-scale cohort study. <i>World Journal of Hepatology</i> , 2018 , 10, 409-416	3.4	2
307	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 177-182	5.1	18

306	HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. <i>HIV Medicine</i> , 2018 , 19, 33-41	2.7	9
305	Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 422-427	9.5	9
304	Non-granulomatous cerebellar infection by <i>Acanthamoeba</i> spp. in an immunocompetent host. <i>Infection</i> , 2018 , 46, 885-889	5.8	9
303	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3460-3470	5.1	7
302	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1949-1954	5.1	14
301	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475	2.7	10
300	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
299	Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2480-2484	5.1	11
298	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1955-1964	5.1	20
297	Laboratory diagnosis of <i>Mycoplasma pneumoniae</i> infections: data analysis from clinical practice. <i>New Microbiologica</i> , 2018 , 41, 203-207	1.1	7
296	<i>Staphylococcus aureus</i> vaccine preclinical and clinical development: current state of the art. <i>New Microbiologica</i> , 2018 , 41, 208-213	1.1	27
295	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2055-2059	5.1	20
294	Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy. <i>Neurological Sciences</i> , 2017 , 38, 1517-1519	3.5	1
293	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ cp/mL. <i>Infection</i> , 2017 , 45, 521-528	5.8	9
292	Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA. <i>Journal of Clinical Virology</i> , 2017 , 91, 18-24	14.5	7
291	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017 , 29, 299-307	2.3	5
290	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 267.e1-267.e4	9.5	7
289	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Iona cohort. <i>PLoS ONE</i> , 2017 , 12, e0177402	3.7	14

288	Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. <i>BMC Infectious Diseases</i> , 2017 , 17, 605	4	11
287	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017 , 17, 734	4	2
286	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2862-2868	5.1	4
285	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
284	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017 , 30, 1253-1265	3	2
283	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , 2017 , 31, 457-459	3.5	32
282	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017 , 31, 487-494	5.8	4
281	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 465-471	3.1	3
280	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. <i>Annals of Internal Medicine</i> , 2017 , 166, 9-17	8	30
279	An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. <i>Aids</i> , 2017 , 31, 417-425	3.5	2
278	Prevalence of M75 Strains Harboring Gene in Patients Affected by Pediatric Obstructive Sleep Apnea Syndrome in Central Italy. <i>Frontiers in Microbiology</i> , 2017 , 8, 294	5.7	4
277	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017 , 12, e0171611	3.7	9
276	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017 , 12, e0187393	3.7	9
275	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017 , 19,	1.5	3
274	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1127-1135	11.6	8
273	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1163-1171	5.1	56
272	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2017 , 64, 680-683	11.6	7
271	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , 2016 , 73, 619-623	18.9	10

270	High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy. <i>Journal of Hepatology</i> , 2016 , 64, S761-S762	13.4	2
269	Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. <i>Journal of Hepatology</i> , 2016 , 64, S763	13.4	3
268	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. <i>Nature Communications</i> , 2016 , 7, 10791	17.4	149
267	Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by <i>Streptococcus pyogenes</i> . <i>Scientific Reports</i> , 2016 , 6, 20609	4.9	8
266	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. <i>Medicine (United States)</i> , 2016 , 95, e5222	1.8	4
265	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016 , 46, 169-179	4.5	32
264	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2663-9	5.1	9
263	Listeria meningoencephalitis and anti-GQ1b antibody syndrome. <i>Infection</i> , 2016 , 44, 543-6	5.8	6
262	Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. <i>HIV Medicine</i> , 2016 , 17, 255-68	2.7	88
261	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016 , 48, 48-55	3.1	5
260	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
259	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016 , 62, 655-663	11.6	117
258	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 288.e1-8	9.5	27
257	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. <i>Journal of Immunoassay and Immunochemistry</i> , 2016 , 37, 189-200	1.8	4
256	A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model. <i>Epidemiology</i> , 2016 , 27, 247-56	3.1	5
255	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016 , 11, e0156360	3.7	
254	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. <i>PLoS ONE</i> , 2016 , 11, e0146097	3.7	16
253	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. <i>PLoS ONE</i> , 2016 , 11, e0156523	3.7	14

252	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 263-71	3.1	33
251	Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. <i>HIV Medicine</i> , 2016 , 17, 385-9	2.7	3
250	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016 , 81, 82-9	14.5	50
249	Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2359-61	5.1	21
248	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3621-3622	5.1	3
247	Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1843-9	5.1	35
246	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv043	1	25
245	Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals. <i>Journal of Infection</i> , 2015 , 70, 60-71	18.9	10
244	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
243	Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients. <i>Antiviral Therapy</i> , 2015 , 20, 433-40	1.6	9
242	Antiretroviral neuropenetrations scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. <i>Antiviral Therapy</i> , 2015 , 20, 441-7	1.6	27
241	Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature. <i>IDCases</i> , 2015 , 2, 109-15	2	12
240	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ, The</i> , 2015 , 350, h3363	5.9	4
239	Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition Model. <i>International Journal of Environmental Research and Public Health</i> , 2015 , 12, 13224-39	4.6	13
238	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015 , 10, e0140877	3.7	7
237	Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naïve patients in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1850-7	5.1	10
236	Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 92, 1257-1260	3.2	9
235	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 14658-63	11.5	108

234	Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. <i>Digestive and Liver Disease</i> , 2015 , 47, 988-993		
233	Evolution of macrolide resistance in <i>Streptococcus pyogenes</i> over 14 years in an area of central Italy. <i>Journal of Medical Microbiology</i> , 2015 , 64, 1186-1195	3.2	14
232	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2015 , 17, 127-34	1.5	6
231	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014 , 14, 79	4	19
230	Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis. <i>Infection</i> , 2014 , 42, 775-8	5.8	6
229	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014 , 42, 61-71	5.8	7
228	Local and global spatio-temporal dynamics of HIV-1 subtype F1. <i>Journal of Medical Virology</i> , 2014 , 86, 186-92	19.7	7
227	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV,the</i> , 2014 , 1, e119-26	7.8	24
226	Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 17-24	1.6	5
225	Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naïve populations beginning treatment: modelling study and economic analysis. <i>Lancet HIV,the</i> , 2014 , 1, e85-93	7.8	33
224	First report of spondylodiscitis due to vancomycin heteroresistant <i>Staphylococcus capitis</i> in immunocompetent host. <i>Journal of Infection and Chemotherapy</i> , 2014 , 20, 639-42	2.2	6
223	Treatment of HCV infection with the novel NS3/4A protease inhibitors. <i>Current Opinion in Pharmacology</i> , 2014 , 18, 9-17	5.1	29
222	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 735-41	5.1	15
221	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. <i>BMC Infectious Diseases</i> , 2014 , 14, 398	4	10
220	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014 , 68, 500-3	18.9	1
219	Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 295-300	3.4	15
218	Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. <i>PLoS ONE</i> , 2014 , 9, e89861	3.7	2
217	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19825-4	5.4	5

216	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19817	5.4	6
215	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 34-45		23
214	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. <i>Journal of Medical Virology</i> , 2014 , 86, 1648-55	19.7	15
213	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3085-94	5.1	6
212	Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics. <i>Journal of Medical Virology</i> , 2014 , 86, 729-36	19.7	21
211	Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. <i>PLoS ONE</i> , 2014 , 9, e109148	3.7	22
210	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014 , 37, 285-306	1.1	
209	HIV tropism and its relationship with transmitted resistance in naive patients. <i>Future Virology</i> , 2013 , 8, 815-820	2.4	
208	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013 , 19, 349-60	4.5	3
207	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , 2013 , 57, 112-21	11.6	45
206	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. <i>BMC Infectious Diseases</i> , 2013 , 13, 414	4	35
205	Combining social and genetic networks to study HIV transmission in mixing risk groups. <i>European Physical Journal: Special Topics</i> , 2013 , 222, 1377-1387	2.3	4
204	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, ATLaS pilot study). <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1364-72	5.1	39
203	Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. <i>Journal of Infectious Diseases</i> , 2013 , 207 Suppl 2, S63-9	7	16
202	Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. <i>PLoS Pathogens</i> , 2013 , 9, e1003515	7.6	86
201	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
200	Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1216-20	7	47
199	Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. <i>Clinical Infectious Diseases</i> , 2013 , 56, 888-97	11.6	76

198	HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1053-6	5.9	31
197	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. <i>Clinical Microbiology and Infection</i> , 2013 , 19, 936-42	9.5	9
196	Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. <i>BMC Infectious Diseases</i> , 2013 , 13, 537	4	3
195	Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 339-45	3.1	11
194	Revised central nervous system neuropenetrance-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. <i>Antiviral Therapy</i> , 2013 , 18, 153-60	1.6	45
193	Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. <i>PLoS ONE</i> , 2013 , 8, e61436	3.7	16
192	Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. <i>PLoS ONE</i> , 2013 , 8, e78642	3.7	5
191	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , 2012 , 12, 119-27	25.5	33
190	Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. <i>Clinical Microbiology and Infection</i> , 2012 , 18, E428-30	9.5	21
189	Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes. <i>AIDS Research and Therapy</i> , 2012 , 9, 13	3	2
188	HIV reservoirs and immune surveillance evasion cause the failure of structured treatment interruptions: a computational study. <i>PLoS ONE</i> , 2012 , 7, e36108	3.7	9
187	HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. <i>PLoS ONE</i> , 2012 , 7, e42223	3.7	16
186	Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission. <i>PLoS ONE</i> , 2012 , 7, e46156	3.7	12
185	Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 984-7	5.1	53
184	Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B. <i>Infection</i> , 2012 , 40, 347-9	5.8	1
183	Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. <i>Journal of Neurochemistry</i> , 2012 , 120, 106-14	6	27
182	Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naïve HIV-infected patients presenting with tuberculosis as AIDS-defining condition. <i>Clinical Infectious Diseases</i> , 2012 , 54, 853-61	11.6	23
181	High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1250-3	5.1	7

180	Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S245-9	11.6	42
179	Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e98-101	3.1	6
178	Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 113-20	3.1	26
177	Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e18-20	3.1	3
176	Determinants of HIV drug resistance and public health implications in low- and middle-income countries. <i>Antiviral Therapy</i> , 2012 , 17, 941-53	1.6	25
175	Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 170-2	3.1	
174	Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 236-44	3.1	19
173	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. <i>Pharmacological Research</i> , 2011 , 63, 249-53	10.2	23
172	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. <i>Vaccine</i> , 2011 , 29, 2836-9	4.1	25
171	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 394-407	25.5	194
170	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 363-71	25.5	292
169	A novel methodology for large-scale phylogeny partition. <i>Nature Communications</i> , 2011 , 2, 321	17.4	93
168	Copy number variation of KIR genes influences HIV-1 control. <i>PLoS Biology</i> , 2011 , 9, e1001208	9.7	111
167	Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. <i>Antiviral Therapy</i> , 2011 , 16, 489-97	1.6	10
166	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. <i>Aids</i> , 2011 , 25, 1041-9	3.5	13
165	Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. <i>HIV Medicine</i> , 2011 , 12, 4-13	2.7	26
164	Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. <i>HIV Medicine</i> , 2011 , 12, 174-82	2.7	4
163	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 1352-5	9.5	6

162	Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011 , 30, 541-9	5.3	9
161	Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. <i>Infection</i> , 2011 , 39, 563-9	5.8	10
160	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , 2011 , 11, 23	4	4
159	A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. <i>BMC Medical Informatics and Decision Making</i> , 2011 , 11, 40	3.6	6
158	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 391-8	19.7	1
157	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. <i>Journal of Infection</i> , 2011 , 62, 319-21	18.9	11
156	Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. <i>Pharmacogenomics</i> , 2011 , 12, 567-76	2.6	32
155	The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1299-309	1.6	12
154	Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. <i>Neurology</i> , 2011 , 76, 1403-9	6.5	185
153	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1886-96	5.1	39
152	Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 163-72	3.1	55
151	Lipid-lowering effect of tenofovir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 682-3	5.1	22
150	Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. <i>PLoS ONE</i> , 2010 , 5, e11505	3.7	48
149	The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies. <i>PLoS ONE</i> , 2010 , 5, e13619	3.7	14
148	Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. <i>Antiviral Therapy</i> , 2010 , 15, 127-9	1.6	11
147	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2050-2	5.1	31
146	Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 784-92	9.7	92
145	Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 411-2	3.1	11

144	Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010 , 42, 81-91	3.3	52
143	Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2010 , 52, 306-7	13.4	3
142	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , 2010 , 170, 410-9		35
141	Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 27-37	4.2	6
140	Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 165-75	1.6	14
139	Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. <i>Lancet Neurology</i> , 2010 , 9, 438-46	24.1	522
138	Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. <i>Retrovirology</i> , 2010 , 7, 56	3.6	47
137	Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. <i>Journal of Medical Virology</i> , 2010 , 82, 1996-2003	19.7	5
136	Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. <i>HIV Medicine</i> , 2010 , 11, 326-33	2.7	20
135	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206 ¹	1.1	35
134	Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 607-15	5.1	29
133	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 109-17	5.1	64
132	Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 261-7	1.6	10
131	Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 305-14	1.6	19
130	Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization. <i>Bioinformatics</i> , 2009 , 25, 1040-7	7.2	8
129	Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African Sites with comprehensive monitoring availability. <i>Clinical Infectious Diseases</i> , 2009 , 48, 115-122	11.6	86
128	Increasing clinical virulence in two decades of the Italian HIV epidemic. <i>PLoS Pathogens</i> , 2009 , 5, e1000454	5.4	30
127	Common genetic variation and the control of HIV-1 in humans. <i>PLoS Genetics</i> , 2009 , 5, e1000791	6	310

126	Determinants of survival in progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2009 , 73, 1551-8	6.5	134
125	Risk of developing specific AIDS-defining illnesses in patients coinfectd with HIV and hepatitis C virus with or without liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2009 , 49, 612-22	11.6	47
124	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 616-24	5.1	33
123	Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. <i>Infection</i> , 2009 , 37, 244-9	5.8	41
122	Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. <i>Infection</i> , 2009 , 37, 270-82	5.8	7
121	Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. <i>Infection</i> , 2009 , 37, 438-44	5.8	3
120	Long-term follow-up of nevirapine-treated patients in a single-centre cohort. <i>HIV Medicine</i> , 2009 , 10, 461-9	2.7	7
119	Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study. <i>Journal of Clinical Virology</i> , 2009 , 46, 290-4	14.5	5
118	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009 , 6, 49	3.6	94
117	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. <i>Antiviral Therapy</i> , 2009 , 14, 359-69	1.6	7
116	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. <i>Antiviral Therapy</i> , 2009 , 14, 359-369	1.6	12
115	Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. <i>HIV Medicine</i> , 2008 , 9, 172-9	2.7	22
114	Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. <i>HIV Medicine</i> , 2008 , 9, 239-45	2.7	14
113	Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. <i>HIV Medicine</i> , 2008 , 9, 519-25	2.7	26
112	Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 710-5	3.4	13
111	Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 149-54	1.6	17
110	Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4050-6	5.9	11
109	Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. <i>Aids</i> , 2008 , 22, 1759-67	3.5	115

108	Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. <i>Infection</i> , 2008 , 36, 244-9	5.8	8
107	Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. <i>Scandinavian Journal of Infectious Diseases</i> , 2007 , 39, 813-8		3
106	Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. <i>Journal of NeuroVirology</i> , 2007 , 13, 338-46	3.9	21
105	Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. <i>Infection</i> , 2007 , 35, 451-6	5.8	3
104	Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1645-53	7	12
103	Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 411-7	3.1	13
102	Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?. <i>Clinical Infectious Diseases</i> , 2007 , 45, 650-3	11.6	6
101	An outbreak of HIV-1 subtype G among Italian injecting drug users. <i>Aids</i> , 2007 , 21, 1213-5	3.5	20
100	Resistance to newly approved and investigational protease inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 130-6	4.2	3
99	A whole-genome association study of major determinants for host control of HIV-1. <i>Science</i> , 2007 , 317, 944-7	33.3	999
98	Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. <i>Antiviral Therapy</i> , 2007 , 12, 835-9	1.6	13
97	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. <i>Antiviral Therapy</i> , 2007 , 12, 1175-1184	1.6	17
96	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1055-64	5.1	5
95	Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2006 , 193, 1219-22	7	23
94	A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. <i>Journal of Infectious Diseases</i> , 2006 , 194, 20-8	7	6
93	Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. <i>Journal of Clinical Virology</i> , 2006 , 35, 414-9	14.5	10
92	The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 352-60	3.1	84
91	Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. <i>Antiviral Therapy</i> , 2006 , 11, 321-7	1.6	4

90	Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. <i>Antiviral Therapy</i> , 2006 , 11, 609-18	1.6	7
89	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. <i>Antiviral Therapy</i> , 2006 , 11, 321-327	1.6	9
88	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. <i>Antiviral Therapy</i> , 2006 , 11, 609-618	1.6	11
87	Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 38, 407-16	3.1	43
86	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2005 , 11, 219-24	3.9	19
85	Impairment of recent thymic emigrants in HCV infection. <i>International Journal of Immunopathology and Pharmacology</i> , 2005 , 18, 723-8	3	17
84	Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals. <i>Journal of Infectious Diseases</i> , 2005 , 192, 703-4; author reply 704-5	7	6
83	A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1000-07	11.6	43
82	Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 4175-7	9.7	97
81	Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. <i>Journal of Infectious Diseases</i> , 2005 , 192, 958-66	7	356
80	Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2005 , 40, e101-9	11.6	43
79	Triple-nucleoside regimens versus efavirenz. <i>New England Journal of Medicine</i> , 2004 , 351, 717-9; author reply 717-9	59.2	4
78	Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 565-71	11.6	102
77	Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 35, 324-6	3.1	15
76	Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. <i>Journal of General Internal Medicine</i> , 2004 , 19, 1104-10	4	51
75	Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 629-34	5.8	7
74	Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. <i>Journal of Clinical Virology</i> , 2004 , 31 Suppl 1, S7-15	14.5	1
73	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2004 , 18, 1602-4	3.5	2

72	The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 641-2	3.1	8
71	Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 35, 359-66	3.1	27
70	Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. <i>Antiviral Therapy</i> , 2004 , 9, 743-52	1.6	5
69	Construction, Training and Clinical Validation of An Interpretation System for Genotypic HIV-1 Drug Resistance Based on Fuzzy Rules Revised by Virological Outcomes. <i>Antiviral Therapy</i> , 2004 , 9, 583-593	1.6	5
68	Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems. <i>Antiviral Therapy</i> , 2004 , 9, 743-752	1.6	12
67	Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. <i>Current Opinion in Infectious Diseases</i> , 2003 , 16, 573-80	5.4	16
66	Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003 , 9 Suppl 1, 47-53	3.9	130
65	Clinical implications of HIV-1 drug resistance in the neurological compartment. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 106, 41-4		17
64	Interpretation systems for genotypic drug resistance of HIV-1. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 106, 29-34		9
63	Discontinuation of secondary prophylaxis for <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOF Study Group. <i>Clinical Infectious Diseases</i> , 2003 , 36, 645-51	11.6	35
62	Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. <i>Journal of Infectious Diseases</i> , 2003 , 187, 1934-43	7	89
61	Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. <i>Aids</i> , 2003 , 17, 1099-102	3.5	51
60	Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfecting patient with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002 , 30, 279-84	3.1	35
59	Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2002 , 68, 479-88	19.7	86
58	Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 835-8	1.6	107
57	Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. <i>Archives of Internal Medicine</i> , 2002 , 162, 2125-32		174
56	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002 , 16, 369-79	3.5	154
55	Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. <i>Neurology</i> , 2002 , 59, 342-7	6.5	77

54	Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 29, 546-7	3.1	3
53	Virologic correlates of adherence to antiretroviral medications and therapeutic failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 31 Suppl 3, S118-22	3.1	43
52	A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2002 , 7, 123-9	1.6	38
51	A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2002 , 7, 123-129	1.6	83
50	Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 49-55	3.1	1
49	Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 326-331	3.1	21
48	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 49-55	3.1	3
47	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. <i>Journal of NeuroVirology</i> , 2001 , 7, 323-8	3.9	56
46	Potent anti-retroviral therapy with or without didanosine for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001 , 7, 364-8	3.9	55
45	Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2001 , 7, 369-74	3.9	3
44	Self-reported nonadherence with antiretroviral drugs predicts persistent condition. <i>HIV Clinical Trials</i> , 2001 , 2, 323-9		29
43	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 28, 114-123 ¹		78
42	Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis. <i>European Journal of Pediatrics</i> , 2001 , 160, 345-50	4.1	96
41	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. <i>Aids</i> , 2001 , 15, 1483-91	3.5	157
40	When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. <i>Aids</i> , 2001 , 15, 983-90	3.5	68
39	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. <i>Aids</i> , 2001 , 15, 1579-81	3.5	59
38	Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. <i>Aids</i> , 2001 , 15, 2325-7	3.5	18
37	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 123-128	3.1	64

36	Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin lymphomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3325-30	2.2	84
35	Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 835-43	1.6	8
34	AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. <i>Neurology</i> , 2000 , 55, 1194-200	6.5	101
33	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 25, 56-62	3.1	28
32	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. <i>Aids</i> , 2000 , 14, 499-507	3.5	390
31	Patient-reported nonadherence to HAART is related to protease inhibitor levels. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 123-8	3.1	105
30	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. <i>Aids</i> , 2000 , 14, F117-21	3.5	52
29	The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. <i>Journal of Infectious Diseases</i> , 2000 , 182, 1077-83	7	94
28	Discontinuation of primary prophylaxis for <i>Pneumocystis carinii</i> pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: the changes in opportunistic prophylaxis study. <i>Journal of Infectious Diseases</i> , 2000 , 181, 1635-42	7	92
27	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. <i>Aids</i> , 2000 , 14, 1655-6	3.5	9
26	Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. <i>Aids</i> , 2000 , 14, 1660-2	3.5	37
25	Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 1999 , 28, 624-8	11.6	50
24	Use of Antiretroviral Therapy by Intravenous Drug Users With HIV. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 281, 699	27.4	8
23	Application of molecular methods for detection and transmission analysis of mycobacterium tuberculosis drug resistance in patients attending a reference hospital in Italy. <i>Journal of Infectious Diseases</i> , 1999 , 179, 1025-9	7	15
22	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , 1999 , 45, 259-261	9.4	34
21	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. <i>Lancet, The</i> , 1999 , 353, 1974	40	15
20	Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. <i>Neurology</i> , 1999 , 52, 891-2	6.5	38
19	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma 1999 , 45, 259		1

18	Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 364-9	9.7	100
17	Changing disease patterns in focal brain lesion-causing disorders in AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 18, 365-71		36
16	HIV-1 infection and progressive multifocal leukoencephalopathy in a person without detectable HIV antibodies. <i>Aids</i> , 1998 , 12, 1251-3	3.5	
15	Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. <i>Neurology</i> , 1997 , 48, 687-94	6.5	181
14	Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997 , 16, 350-6		38
13	Non specific PCR products using rat-derived <i>Pneumocystis carinii</i> dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples. <i>Molecular and Cellular Probes</i> , 1996 , 10, 187-90	3.3	7
12	Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. <i>European Neurology</i> , 1996 , 36, 125-33	2.1	32
11	Comparison of two PCR methods for detection of <i>Pneumocystis carinii</i> in bronchoalveolar lavage fluid. <i>Journal of Eukaryotic Microbiology</i> , 1996 , 43, 205	3.6	8
10	Detection of <i>Pneumocystis carinii</i> DNA in HIV patients with <i>P. carinii</i> pneumonia (PCP) and in animal models. <i>Journal of Eukaryotic Microbiology</i> , 1996 , 43, 185-195	3.6	
9	PCR detection of <i>Toxoplasma gondii</i> DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. <i>Journal of Medical Microbiology</i> , 1996 , 45, 472-6	3.2	56
8	Imbalance between <i>Pneumocystis carinii</i> cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. <i>Journal of Medical Microbiology</i> , 1996 , 45, 146-8	3.2	15
7	Role of <i>Pneumocystis carinii</i> DNA amplification by PCR on the diagnosis of <i>Pneumocystis carinii</i> pneumonia in patients with haematologic malignant diseases: report of four cases. <i>Acta Haematologica</i> , 1995 , 94, 163-6	2.7	3
6	Presumptive clinical criteria versus endoscopy in the diagnosis of <i>Candida</i> esophagitis at various HIV-1 disease stages. <i>Endoscopy</i> , 1995 , 27, 371-6	3.4	12
5	Variable efficiency of three primer pairs for the diagnosis of <i>Pneumocystis carinii</i> pneumonia by the polymerase chain reaction. <i>Molecular and Cellular Probes</i> , 1995 , 9, 333-40	3.3	15
4	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia and toxoplasmic encephalitis. <i>Aids</i> , 1995 , 9, 1343-50	3.5	47
3	Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 1995 , 90, 844-9	4.5	104
2	Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet, The</i> , 1992 , 340, 788	4.0	12
1	<i>Pneumocystis carinii</i> stimulates in vitro production of tumor necrosis factor-alpha by human macrophages. <i>Medical Microbiology and Immunology</i> , 1991 , 180, 15-20	4	26

